Literature DB >> 26666640

The Deubiquitylase USP2 Regulates the LDLR Pathway by Counteracting the E3-Ubiquitin Ligase IDOL.

Jessica Kristine Nelson1, Vincenzo Sorrentino1, Rossella Avagliano Trezza1, Claire Heride1, Sylvie Urbe1, Ben Distel1, Noam Zelcer2.   

Abstract

RATIONALE: The low-density lipoprotein (LDL) receptor (LDLR) is a central determinant of circulating LDL-cholesterol and as such subject to tight regulation. Recent studies and genetic evidence implicate the inducible degrader of the LDLR (IDOL) as a regulator of LDLR abundance and of circulating levels of LDL-cholesterol in humans. Acting as an E3-ubiquitin ligase, IDOL promotes ubiquitylation and subsequent lysosomal degradation of the LDLR. Consequently, inhibition of IDOL-mediated degradation of the LDLR represents a potential strategy to increase hepatic LDL-cholesterol clearance.
OBJECTIVE: To establish whether deubiquitylases counteract IDOL-mediated ubiquitylation and degradation of the LDLR. METHODS AND
RESULTS: Using a genetic screening approach, we identify the ubiquitin-specific protease 2 (USP2) as a post-transcriptional regulator of IDOL-mediated LDLR degradation. We demonstrate that both USP2 isoforms, USP2-69 and USP2-45, interact with IDOL and promote its deubiquitylation. IDOL deubiquitylation requires USP2 enzymatic activity and leads to a marked stabilization of IDOL protein. Paradoxically, this also markedly attenuates IDOL-mediated degradation of the LDLR and the ability of IDOL to limit LDL uptake into cells. Conversely, loss of USP2 reduces LDLR protein in an IDOL-dependent manner and limits LDL uptake. We identify a tri-partite complex encompassing IDOL, USP2, and LDLR and demonstrate that in this context USP2 promotes deubiquitylation of the LDLR and prevents its degradation.
CONCLUSIONS: Our findings identify USP2 as a novel regulator of lipoprotein clearance owing to its ability to control ubiquitylation-dependent degradation of the LDLR by IDOL.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  E3 ubiquitin ligase; LDL cholesterol; LDL receptors; MYLIP/IDOL; USP2; ubiquitin

Mesh:

Substances:

Year:  2015        PMID: 26666640     DOI: 10.1161/CIRCRESAHA.115.307298

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  16 in total

1.  The Degron Architecture of Squalene Monooxygenase and How Specific Lipids Calibrate Levels of This Key Cholesterol Synthesis Enzyme.

Authors:  Ngee Kiat Chua; Andrew J Brown
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  LXR Regulation of Brain Cholesterol: From Development to Disease.

Authors:  Rebecca Courtney; Gary E Landreth
Journal:  Trends Endocrinol Metab       Date:  2016-04-21       Impact factor: 12.015

3.  Foiling IDOL to Help Control Cholesterol.

Authors:  Andrew J Brown; Joanne Hsieh
Journal:  Circ Res       Date:  2016-02-05       Impact factor: 17.367

Review 4.  Sex differences in cardiometabolic disorders.

Authors:  Eva Gerdts; Vera Regitz-Zagrosek
Journal:  Nat Med       Date:  2019-11-07       Impact factor: 53.440

5.  Macrophage ubiquitin-specific protease 2 modifies insulin sensitivity in obese mice.

Authors:  Natsuko Saito; Shunsuke Kimura; Tomomi Miyamoto; Sanae Fukushima; Misato Amagasa; Yoshinori Shimamoto; Chieko Nishioka; Shiki Okamoto; Chitoku Toda; Kohei Washio; Atsushi Asano; Ichiro Miyoshi; Eiki Takahashi; Hiroshi Kitamura
Journal:  Biochem Biophys Rep       Date:  2017-01-26

6.  Integration of cellular ubiquitin and membrane traffic systems: focus on deubiquitylases.

Authors:  Michael J Clague; Sylvie Urbé
Journal:  FEBS J       Date:  2017-01-29       Impact factor: 5.542

7.  The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.

Authors:  Jinrui Zhang; Shuyan Liu; Qiong Li; Yulin Shi; Yueguang Wu; Fang Liu; Shanshan Wang; Mohamed Y Zaky; Waleed Yousuf; Qianhui Sun; Dong Guo; Taishu Wang; Yingqiu Zhang; Yang Wang; Man Li; Han Liu
Journal:  Cell Death Differ       Date:  2020-04-23       Impact factor: 15.828

8.  Inhibition of ubiquitin-specific protease 2 causes accumulation of reactive oxygen species, mitochondria dysfunction, and intracellular ATP decrement in C2C12 myoblasts.

Authors:  Mayuko Hashimoto; Natsuko Saito; Haru Ohta; Kumiko Yamamoto; Asuka Tashiro; Kosuke Nakazawa; Osamu Inanami; Hiroshi Kitamura
Journal:  Physiol Rep       Date:  2019-07

9.  The Association Between Vitamin D and Multiple Sclerosis Risk: 1,25(OH)2D3 Induces Super-Enhancers Bound by VDR.

Authors:  Ming Lu; Bennet J McComish; Kathryn P Burdon; Bruce V Taylor; Heinrich Körner
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

10.  Downregulation of ubiquitin-specific protease 2 possesses prognostic and diagnostic value and promotes the clear cell renal cell carcinoma progression.

Authors:  Xiangui Meng; Zhiyong Xiong; Wen Xiao; Changfei Yuan; Cheng Wang; Yu Huang; Junwei Tong; Jian Shi; Zhixian Chen; Chenchen Liu; Kairu Xie; Hailong Xiong; Ke Chen; Hongmei Yang; Xiaoping Zhang
Journal:  Ann Transl Med       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.